Current pharmacotherapy of benign prostatic hyperplasia
Authors:
V. Hanáček 1; T. Hanuš 2
Authors‘ workplace:
Institut klinické a experimentální medicíny, Praha, Klinika transplantační chirurgie, Přednosta: prof. MUDr. Jiří Froněk, PhD.
1; Urologická klinika 1. LF UK a VFN, Praha a Katedra urologie IPVZ, Praha, Přednosta: prof. MUDr. Viktor Soukup, Ph. D.
2
Published in:
Prakt. Lék. 2024; 104(3): 107-111
Category:
Reviews
Overview
Benign prostatic hyperplasia is a frequent disease in older men. Although mortality is low, in developed countries, it has a significant morbidity, leading to a decrease in quality of life in a large number of men. As the population ages, so does the number of men with benign prostatic hyperplasia requiring treatment. Pharmacotherapy is the first line of treatment. Its main goal is to reduce symptoms’ severity, slow their progression, and delay invasive surgical treatment for as long as possible. We currently have several drug categories with which we can achieve these goals. Our paper aims to summarise the drug categories used in modern pharmacotherapy of prostatic hyperplasia, describe their specifics, and list those drugs that have achieved wide application in clinical practice.
Keywords:
combination therapy – Benign prostatic hyperplasia – alpha-blockers – 5-alpha-reductase inhibitors – antimuscarinics
Sources
- Jocham D, Miller K. Praxis in der Urologie. Stuttgart: Georg Thieme Verlag 2007.
- Povýšil C, Šteiner I, a kol. Speciální patologie. Praha: Galén 2007.
- Matoušková M, a kol. Praktická urologie v kazuistikách. Praha: Axonite CZ 2013.
- Zámečník L, a kol. Moderní farmakoterapie v urologii. Praha: Maxdorf 2019.
- European Association of Urology. EAU Guidelines [online]. Dostupné z: https://uroweb.org/guidelines [cit. 2024-06-15].
- Noble AJ, Chess-Williams R, Couldwell C, et al. The effects of tamsulosin, a high affinity antagonist at functional alpha 1Aand alpha 1D-adrenoceptor subtypes. Br J Pharmacol. 1997; 120(2): 231–238.
- Záleský M. Konzervativní terapie non-neurogenních dysfunkcí dolních močových cest. Urol praxi. 2021; 22(2): 65–69.
- Lukeš M, Heráček J. Benigní hyperplazie prostaty – kombinovaná léčba alfablokátory a inhibitory 5-alfa reduktázy. Urolog pro Praxi 2009; 10(5): 279–281.
- McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003; 349(25): 2387–2398.
- Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4 year results from the CombAT study. Eur Urol. 2010; 57(1): 123–131.
- Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology 2019; 65(5): 458–464.
- Li Y, Ma J, Qin XH, Hu CY. The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis. Transl Androl Urol. 2022; 11(3): 313–324.
- Kuiper JG, Bezemer ID, Driessen MT, et al. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride. BMC Urol. 2016; 16(1): 53.
- Kaplan SA, Lee JY, Meehan AG, et al. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol. 2011; 185(4): 1369–1373.
- Armitage J, Emberton M. The role of anticholinergic drugs in men with lower urinary tract symptoms. Curr Opin Urol. 2008; 18(1): 11–15.
- Rees J, Foley S, Huang M, et al. Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe. Neurourol Urodyn. 2019; 38(3): 981–989.
- Dvořáček J. Kombinovaná léčba benigní hyperplazie prostaty. Urol Praxi. 2012; 13(4): 148–153.
- Füllhase C, Chapple C, Cornu JN, et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol. 2013; 64(2): 228–243.
- Matoušková M, Hanuš M. Kombinovaná léčba u symptomů dolních močových cest a benigní hyperplazie prostaty. Urolog pro Praxi 2011; 12(1): 7–11.
- Novara G, Galfano A, Ficarra V, et al. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: A systematic review. Eur Urol. 2006; 50(4): 675–683.
- Csikós E, Horváth A, Ács K, et al. Treatment of benign prostatic hyperplasia by natural drugs. Molecules 2021; 26(23): 7141.
adresa pro korespondenci:
MUDr. Vítězslav Hanáček
Klinika transplantační chirurgie IKEM
Vídeňská 1958/9, 140 21 Praha 4
e-mail: haav@ikem.cz
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2024 Issue 3
Most read in this issue
- Vaccination against Covid-19 - IgG antibodies, CIC and complement components in serum
- Values related to feelings of loss of dignity in patients with rheumatological diseases
- Is the different socioeconomic status of families a source of differences in physical activity, sleep, and sedentary behaviour in children 3–8-year-old?
- Current pharmacotherapy of benign prostatic hyperplasia